Semaglutide

A cikin Disamba 2017, Hukumar Abinci da Magunguna ta Amurka (FDA) ta amince da jerin alluran Smeglugan peptide don sarrafa abinci na taimako da motsa jiki don haɓaka sarrafa glucose na jini na marasa lafiya da nau'in ciwon sukari na 2.Bugu da kari, Novo da Nord suma sun kirkiri nau'in maganin baka na Rybelsus na Smeglugin, kuma FDA ta fara amincewa da ita a watan Satumba na 2019. Wannan kuma shine farkon yarda da maganin GLP-1 na baka a duniya.ciwon sukari.A haƙiƙa, Smeglugin magani ne na hypoglycemic, amma saboda magunguna irin su Smeglugin peptide na iya rage yawan ciki kuma yana hana ci, zai rage nauyi.

Dangane da wannan, a cikin Yuni 2021, FDA a hukumance ta amince da sarrafa nauyi na dogon lokaci na kiba ko manya masu kiba.Mutanen da suka dace sune: marasa lafiya masu sauƙi tare da BMI ≥30 kg / m2;da BMI> 27 kg/m2 kuma suna haɗuwa aƙalla rikicewar kiba guda ɗaya, kamar hauhawar jini, nau'in ciwon sukari na 2, ko ƙarancin lipids na jini.Hakanan wannan amincewar an binne shi don Smeglugin akan hanyar "maganin asarar nauyi".

A cikin Afrilu 2021, an amince da Smegugan a China don sarrafa sukarin jini ga marasa lafiya da ke da nau'in ciwon sukari na 2 (T2DM).Ko da yake ba a yarda da alamar asarar nauyi a kasar Sin ba, ba za a iya gudanar da buƙatun asarar nauyi a cikin gida a kasar Sin ba.Bugu da kari, babban jigo na "bakin ciki tare da bakin ciki", a cikin rabin na biyu na 2022 Smeglugin peptide "bai yarda" a fagen nauyi asara., Da zarar a kan dandamali na e-commerce da yawa, ya kafa haɓakar siyayya, kuma sau ɗaya ya zama babban farashin "fiye da sarkin hannun jari", wanda kai tsaye ya haifar da matsalolin samarwa da samar da masana'anta.Nuo da Nord's Yuli na bara sun ce sake dawo da samar da magunguna zai dakatar da samar da kasuwannin asibiti.

An kuma tabbatar da shaharar Smegugu peptide daga bayanan kudi na Nuo da Nord.Dangane da sakamakon 2022 na baya-bayan nan da Nuo da Nord suka sanar, kudaden shiga na shekara-shekara na kasuwancin Nuo da Nord na GLP-1 ya kai biliyan 83.371 Dan Ying Crown (daidai da yuan biliyan 81.6), karuwar da kashi 56% a duk shekara.Daga cikin su, cinikin Smeglugin ya kai dala biliyan 59.75 Dan Ying Crown (daidai da yuan biliyan 58.5), wanda ya karu da kashi 77 cikin 100 na shekara.Ayyukan tallace-tallace na samfuran GLP-1 a fagen jiyya na nau'in ciwon sukari na 2 a China ya karu da 102% a cikin Dan Ying Krone.

Tabbas, fashewar Smeglugin a fagen asarar nauyi yana da alaƙa da babban tasirin sa."Lokaci ya yi don ci, sha da sha, ɗaukar nauyin kilo 5, rasa kilo 30 a watan Janairu" da sauransu.Bugu da kari, "kwance kwance" na iya zama sirara, wanda ya jawo idanu marasa adadi ga Smegtu peptides, da aka sani da "maganin asarar nauyi".Duk da haka, wasu likitocin sun bayyana cewa Simei Gulu peptide yana da fiye da 2/3 na tallace-tallace na gida a kasar Sin don rasa nauyi, ba ciwon sukari ba.A gefe guda Dangane da Smeglugan peptide a matsayin maganin sayan magani, akwai haɗarin ɓoye a cikin amincin magungunan superpatient.

Yana da kyau a lura cewa ƙarshen binciken gida na irin waɗannan magungunan ya samo asali ne daga manyan marasa lafiya masu kiba.Ga mutanen da ke da ɗan kitse ko ma nauyin al'ada (BM <27kg/m2), fa'idodi da haɗarin haɗari har yanzu ba a san su ba.Bugu da kari, baya ga halayen hypoglycemia wadanda sune magungunan hypogenal da ke faruwa a cikin magungunan hypoglycemic, halayen gastrointestinal sun yi fice, kuma abin da ya faru na tashin zuciya, maƙarƙashiya, amai da gudawa ya kai 82.8%.7%.Abu mafi mahimmanci shine Smeglugin ba a yarda da shi ba don alamun asarar nauyi a China.Matsalar tashoshi na magunguna da amfani da miyagun ƙwayoyi na irin waɗannan mutane ya cancanci kulawa.